Biotechnology News and Research

RSS

Akela Pharma fourth-quarter consolidated net loss increases to $14.1M

Akela Pharma, Inc., a leader in the development of therapeutics for the treatment of pain, and the company's wholly owned subsidiary, PharmaForm, today announced its financial results for the three months and year ended December 31, 2009.

1 Jun 2010

Chakra Biotech Sdn Bhd announces name change to Cerca Insights Sdn Bhd

Chakra Biotech Sdn Bhd today announced its name change to Cerca Insights Sdn Bhd. The name change follows the recent completion of a Series B investment round with Malaysian Life Sciences Capital Fund Ltd and the Malaysian Technology Development Corporation Sdn Bhd.

31 May 2010

Karolinska Institutet researchers produce human stem cells without using animal substances

For the first time, human embryonic stem cells have been cultured under chemically controlled conditions without the use of animal substances, which is essential for future clinical uses. The method has been developed by researchers at Karolinska Institutet and is presented in the journal Nature Biotechnology.

31 May 2010

Illinois General Assembly passes Angel Tax Credit with overwhelming bipartisan support

The Illinois General Assembly late yesterday passed—with overwhelming bipartisan support—an Angel Tax Credit that incentivizes early-stage investment in Illinois technology companies. The Governor, whose office worked hard to pass the credit, is expected to sign the bill (SB 2093) or a second measure (SB 3710) with an identical Angel Tax Credit sent to the Senate yesterday by the House.

31 May 2010

Mucosis receives € 3M innovation credit line from Dutch Ministry for development of FluGEM influenza vaccine

Dutch vaccine development company Mucosis B.V. announced today that it has received an innovation credit line of approximately € 3 million from Agentschap NL, an agency of the Dutch Ministry of Economic Affairs. Mucosis will use this loan towards the clinical development of its lead product FluGEM™, an influenza vaccine that can be administered by a simple spray in the nose. The loan will be redeemed only if the FluGEM™ clinical development program is concluded successfully.

31 May 2010

Celladon announces 6-month data from Phase 2 clinical trial of MYDICAR in advanced heart failure patients

Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that six-month data from its Phase 2 clinical trial of MYDICAR® show improvements in clinical outcomes and disease markers in advanced heart failure patients treated with the genetically targeted enzyme replacement therapy.

31 May 2010

BioTime offers 5 new human stem cell lines developed using ACTCellerate technology for research use

BioTime, Inc. announced today that on June 1, 2010 the Company will be offering for sale five new human stem cell lines for research use only. These cell lines were developed using BioTime's ACTCellerate™ technology. These highly purified, novel, and scalable cell lines are embryonic progenitors, meaning that they are intermediate between human embryonic stem cells and fully developed cells.

31 May 2010

Targeted Genetics's partner Celladon presents Phase II trial data with MYDICAR at Heart Failure Congress 2010

Targeted Genetics Corporation announced that its partner, Celladon Corporation, presented full data today that show the first Phase II trial with MYDICAR® for the treatment of advanced heart failure has met its primary safety and efficacy endpoints, as prospectively defined in the Phase II trial protocol.

31 May 2010

Yeast produce a hormone that triggers fungal cells to become more infectious

In their ongoing studies of how yeast (fungi) can infect a host and cause disease, a research team at the Life Sciences and Bioengineering Center at Worcester Polytechnic Institute (WPI) has made an unexpected discovery. They found that yeast produce a hormone previously known to be made by plants, and that the presence of that hormone in sufficient quantity within the yeast's immediate environment triggers the fungal cells to become more infectious.

29 May 2010

Various aspects of consumer genetics to be discussed at 2nd Annual Consumer Genetics Conference

At the 2nd Annual Consumer Genetics Conference taking place in Boston from June 2-4 at the Hynes Convention Center, these issues will be addressed and preeminent leaders from varying areas of expertise will provide perspectives on these crucial topics that are shaping the way we approach clinical medicine and helping to improve patient outcomes.

29 May 2010

Bioheart to establish two Centers of Excellence to provide cell therapy procedures for patients with CHF, PAD

Bioheart, Inc., announced today plans for establishing two Centers of Excellence in the Middle East to provide its cell therapy procedures to patients suffering from congestive heart failure and peripheral arterial disease. Dr. Karl E. Groth, Chairman and CEO, and Peggy A. Farley, Chief Operating and Financial Officer, are now in that region holding discussions and performing site inspections.

29 May 2010

Safety rules lag in biotech industry

The New York Times reports that safety rules for biotechnology workers sometimes expose them to dangerous pathogens. "Whether handling deadly pathogens for biowarfare research, harnessing viruses to do humankind's bidding or genetically transforming cells to give them powers not found in nature, the estimated 232,000 employees in the nation's most sophisticated biotechnology labs work amid imponderable hazards. And some critics say the modern biolab often has fewer federal safety regulations than a typical blue-collar factory."

29 May 2010

Cross Country Healthcare extends revolving credit facility, reduces principal amount to $50M

Cross Country Healthcare, Inc. today announced the refinancing of its revolving loan credit facility and extension of the maturity date by approximately three years. The Company also elected to reduce the aggregate principal amount of the revolving credit facility to $50.0 million. The revolving credit facility was undrawn upon the closing of the refinancing.

29 May 2010

Hitachi Software, OriGene announce co-marketing agreement

Hitachi Software Engineering America, Ltd. and OriGene Technologies, Inc. today announced a co-marketing agreement to jointly promote OriGene's multiplex assays built on Luminex xMAP/Bio-Plex technology and Hitachi Software's MasterPlex software suite for analysis and reporting of multiplex assay data.

29 May 2010

Life Technologies acquires majority stake in Geneart

Life Technologies Corporation, a provider of innovative life science solutions, announced today that it has concluded its tender offer and acquired a majority stake in Geneart AG, the global leader of the synthetic gene market segment. The combination of Geneart with Life Technologies' resources and commercial capabilities creates a well-capitalized synthetic biology company with advanced technology and production capabilities, providing products to fuel innovation in this emerging field.

28 May 2010

Advaxis doses first patient in FDA-approved phase II CIN trial

Advaxis, Inc., the live, attenuated Listeria monocytogenes biotechnology company, has dosed the first patient in its US Food and Drug Administration -approved, phase II clinical trial in cervical intraepithelial neoplasia, commonly known as cervical dysplasia.

28 May 2010

Amorfix, Aragen Bioscience collaborate to develop high-affinity monoclonal antibodies against targets for cancer

Amorfix Life Sciences and Aragen Bioscience, Inc. announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Using its proprietary ProMIS(TM) computational platform discovery technology, Amorfix has identified several disease specific epitopes ("DSEs") on misfolded Fas receptor. Aragen will use those DSEs to generate highly specific monoclonal antibodies ("mAbs").

28 May 2010

Researchers see plectasin as promising lead compound for new antibiotics

An active compound from fungi and lower animals may well be suitable as an effective weapon against dangerous bacteria. We're talking about plectasin, a small protein molecule that can even destroy highly resistant bacteria . Researchers at the Universities of Bonn, Utrecht, Aalborg and of the Danish company Novozymes AS have shed light on how the substance does this.

28 May 2010

Discovery may pave way to help reduce health hazards

A discovery that may pave the way to helping reduce health hazards such as E. coli in water could also make chemicals and drugs such as insulin cheaper to produce and their production more environmentally friendly.

28 May 2010

Amgen announces European approval of Prolia

Amgen Inc. today announced that the European Commission (EC) has granted marketing authorization for Prolia® (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.

28 May 2010

Biotechnology News and Research

Akela Pharma fourth-quarter consolidated net loss increases to $14.1M

Chakra Biotech Sdn Bhd announces name change to Cerca Insights Sdn Bhd

Karolinska Institutet researchers produce human stem cells without using animal substances

Illinois General Assembly passes Angel Tax Credit with overwhelming bipartisan support

Mucosis receives € 3M innovation credit line from Dutch Ministry for development of FluGEM influenza vaccine

Celladon announces 6-month data from Phase 2 clinical trial of MYDICAR in advanced heart failure patients

BioTime offers 5 new human stem cell lines developed using ACTCellerate technology for research use

Targeted Genetics's partner Celladon presents Phase II trial data with MYDICAR at Heart Failure Congress 2010

Yeast produce a hormone that triggers fungal cells to become more infectious

Various aspects of consumer genetics to be discussed at 2nd Annual Consumer Genetics Conference

Bioheart to establish two Centers of Excellence to provide cell therapy procedures for patients with CHF, PAD

Safety rules lag in biotech industry

Cross Country Healthcare extends revolving credit facility, reduces principal amount to $50M

Hitachi Software, OriGene announce co-marketing agreement

Life Technologies acquires majority stake in Geneart

Advaxis doses first patient in FDA-approved phase II CIN trial

Amorfix, Aragen Bioscience collaborate to develop high-affinity monoclonal antibodies against targets for cancer

Researchers see plectasin as promising lead compound for new antibiotics

Discovery may pave way to help reduce health hazards

Amgen announces European approval of Prolia

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News